Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature With Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature With Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced it will be holding a virtual corporate R&D event on April 24th, 2024 from 4:15 p.m. to 5:30 p.m. ET. The agenda will feature presentations by Acrivon's leadership team followed by an interactive Q&A session.
"We are very excited to share key updates across our AP3-driven pipeline and to highlight the power of employing our precision phosphoproteomics-based approach both for drug discovery and development," said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. "We also look forward to sharing initial ACR-368 clinical data based on prospective patient responder identification with our ACR-368 OncoSignature assay, as well as preclinical updates on ACR-2316, our internally discovered, potent, single agent active WEE1/PKMYT1 inhibitor, and other pipeline progress. We will also provide a demonstration of our proprietary, machine learning-enabled AP3 Interactome, an interactive tool we leverage to uncover actionable drug-induced pathway effects across all our studies."
A live webcast of the event will be available through a link on the Events & Presentations page within the investor section of the company's website. The webcast will be available for at least 30 days following the event.
馬薩諸塞州沃特敦,2024年4月16日(環球新聞專線)——Acrivon Therapeutics, Inc.(“Acrivon” 或 “Acrivon Therapeutics”)(納斯達克股票代碼:ACRV),一家臨床階段的生物製藥公司,利用其專有的基於蛋白質組學的患者反應者識別平台Acrivon Predictive,開發精準腫瘤藥物,與預計腫瘤對每種特定藥物敏感的患者相匹配精密蛋白組學(AP3)今天宣佈將在美國東部時間2024年4月24日下午 4:15 至 5:30 舉行虛擬企業研發活動。該議程將包括Acrivon領導團隊的演講,隨後是互動問答環節。
Acrivon Therapeutics首席執行官、總裁兼創始人Peter Blume-Jensen醫學博士、博士表示:“我們很高興分享我們由AP3驅動的產品線中的關鍵更新,並強調採用我們基於精確磷酸蛋白質組學的方法進行藥物發現和開發的力量。”“我們還期待通過我們的 ACR-368 oncoSignature 測定分享基於前瞻患者反應者識別的 ACR-368 初步臨床數據,以及我們內部發現的強效單藥活性 WEE1/PKMYT1 抑制劑 ACR-2316 的臨床前更新以及其他研發進展。我們還將演示我們專有的、支持機器學習的AP3 Interactome,這是一款交互式工具,我們在所有研究中發現可操作的藥物誘發路徑效應。”
該活動的網絡直播將通過公司網站 “投資者” 部分的 “活動與演示” 頁面上的鏈接進行直播。網絡直播將在活動結束後至少 30 天內播出。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧